<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Stoke Therapeutics Inc — News on 6ix</title>
    <link>https://6ix.com/company/stoke-therapeutics-inc</link>
    <description>Latest news and press releases for Stoke Therapeutics Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 14 Apr 2026 14:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/stoke-therapeutics-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835c4f878dffbe2df11a68c.webp</url>
      <title>Stoke Therapeutics Inc</title>
      <link>https://6ix.com/company/stoke-therapeutics-inc</link>
    </image>
    <item>
      <title>Zealand Pharma Appoints Eric Rojas as Vice President and Head of Investor Relations</title>
      <link>https://6ix.com/company/stoke-therapeutics-inc/news/zealand-pharma-appoints-eric-rojas-as-vice-president-and-head-of-investor-relations-2</link>
      <guid isPermaLink="true">https://6ix.com/company/stoke-therapeutics-inc/news/zealand-pharma-appoints-eric-rojas-as-vice-president-and-head-of-investor-relations-2</guid>
      <pubDate>Tue, 14 Apr 2026 14:00:00 GMT</pubDate>
      <description>Eric Rojas VP, Head of Investor Relations Press release – No. 7 / 2026 Zealand Pharma Appoints Eric Rojas as Vice President and Head of Investor Relations Bringing significant experience from Vertex Pharmaceuticals and Shire Copenhagen, Denmark and Boston, Massachusetts, April 14, 2026 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced the appointment of Eric Rojas, Vice President, Investor Relations, effec</description>
    </item>
    <item>
      <title>Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference</title>
      <link>https://6ix.com/company/stoke-therapeutics-inc/news/stoke-therapeutics-to-present-at-the-25th-annual-needham-virtual-healthcare-conference</link>
      <guid isPermaLink="true">https://6ix.com/company/stoke-therapeutics-inc/news/stoke-therapeutics-to-present-at-the-25th-annual-needham-virtual-healthcare-conference</guid>
      <pubDate>Wed, 08 Apr 2026 20:01:00 GMT</pubDate>
      <description>BEDFORD, Mass., April 08, 2026--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith will present at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, Apri</description>
    </item>
    <item>
      <title>Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors</title>
      <link>https://6ix.com/company/stoke-therapeutics-inc/news/stoke-therapeutics-appoints-clare-kahn-phd-to-its-board-of-directors</link>
      <guid isPermaLink="true">https://6ix.com/company/stoke-therapeutics-inc/news/stoke-therapeutics-appoints-clare-kahn-phd-to-its-board-of-directors</guid>
      <pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
      <description>BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing</description>
    </item>
    <item>
      <title>The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome</title>
      <link>https://6ix.com/company/stoke-therapeutics-inc/news/the-new-england-journal-of-medicine-publishes-first-data-to-demonstrate-the-potential-for-disease-modification-in-dravet-syndrome-5</link>
      <guid isPermaLink="true">https://6ix.com/company/stoke-therapeutics-inc/news/the-new-england-journal-of-medicine-publishes-first-data-to-demonstrate-the-potential-for-disease-modification-in-dravet-syndrome-5</guid>
      <pubDate>Wed, 04 Mar 2026 05:00:00 GMT</pubDate>
      <description>–Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with this rare, devastating genetic</description>
    </item>
    <item>
      <title>Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference</title>
      <link>https://6ix.com/company/stoke-therapeutics-inc/news/stoke-therapeutics-to-present-at-the-td-cowen-46th-annual-health-care-conference</link>
      <guid isPermaLink="true">https://6ix.com/company/stoke-therapeutics-inc/news/stoke-therapeutics-to-present-at-the-td-cowen-46th-annual-health-care-conference</guid>
      <pubDate>Tue, 24 Feb 2026 05:00:00 GMT</pubDate>
      <description>BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing</description>
    </item>
    <item>
      <title>Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)</title>
      <link>https://6ix.com/company/stoke-therapeutics-inc/news/stoke-therapeutics-announces-first-patient-123000760</link>
      <guid isPermaLink="true">https://6ix.com/company/stoke-therapeutics-inc/news/stoke-therapeutics-announces-first-patient-123000760</guid>
      <pubDate>Wed, 11 Feb 2026 12:30:00 GMT</pubDate>
      <description>BEDFORD, Mass., February 11, 2026--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today announced that the first patient has been dosed in the Phase 1 OSPREY study of STK-002, an investigational medicine for the treatment of Autosomal Dominant Optic Atrophy (ADOA). ADOA is a rare genetic disease that causes progressive and irreversible vision loss in both eyes starting in the first d</description>
    </item>
    <item>
      <title>Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026</title>
      <link>https://6ix.com/company/stoke-therapeutics-inc/news/stoke-therapeutics-present-guggenheim-emerging-210100672</link>
      <guid isPermaLink="true">https://6ix.com/company/stoke-therapeutics-inc/news/stoke-therapeutics-present-guggenheim-emerging-210100672</guid>
      <pubDate>Wed, 04 Feb 2026 21:01:00 GMT</pubDate>
      <description>BEDFORD, Mass., February 04, 2026--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday,</description>
    </item>
    <item>
      <title>Anchor Line Partners Supports Stoke Therapeutics&apos; Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA</title>
      <link>https://6ix.com/company/stoke-therapeutics-inc/news/anchor-line-partners-supports-stoke-190500727</link>
      <guid isPermaLink="true">https://6ix.com/company/stoke-therapeutics-inc/news/anchor-line-partners-supports-stoke-190500727</guid>
      <pubDate>Tue, 27 Jan 2026 19:05:00 GMT</pubDate>
      <description>Anchor Line Partners, LLC and Northwood Investors, LLC announced today that they have secured a significant long-term lease with biotechnology company Stoke Therapeutics (Nasdaq: STOK) at 245 Fifth Avenue in Waltham, Massachusetts. Stoke plans to relocate to its new 98,500 square-foot headquarters when the Company&apos;s current lease in Bedford, Massachusetts ends in late 2026.</description>
    </item>
    <item>
      <title>Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)</title>
      <link>https://6ix.com/company/stoke-therapeutics-inc/news/stoke-therapeutics-announces-inducement-grants-210100173</link>
      <guid isPermaLink="true">https://6ix.com/company/stoke-therapeutics-inc/news/stoke-therapeutics-announces-inducement-grants-210100173</guid>
      <pubDate>Fri, 16 Jan 2026 21:01:00 GMT</pubDate>
      <description>BEDFORD, Mass., January 16, 2026--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on January 15, 2026, it granted stock options to purchase an aggregate of 74,020 shares of common stock to nine</description>
    </item>
    <item>
      <title>Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome</title>
      <link>https://6ix.com/company/stoke-therapeutics-inc/news/stoke-therapeutics-announces-updates-timelines-completion-enrollment-and-phase-3-data</link>
      <guid isPermaLink="true">https://6ix.com/company/stoke-therapeutics-inc/news/stoke-therapeutics-announces-updates-timelines-completion-enrollment-and-phase-3-data</guid>
      <pubDate>Sun, 11 Jan 2026 05:00:00 GMT</pubDate>
      <description>— Company now expects to complete enrollment of 150 patients in Q2 2026, with a Phase 3 data readout in mid-2027; Rolling NDA submission planned to initiate</description>
    </item>
    <item>
      <title>Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
      <link>https://6ix.com/company/stoke-therapeutics-inc/news/stoke-therapeutics-present-44th-annual-jp-morgan-healthcare-conference-2026-01-06</link>
      <guid isPermaLink="true">https://6ix.com/company/stoke-therapeutics-inc/news/stoke-therapeutics-present-44th-annual-jp-morgan-healthcare-conference-2026-01-06</guid>
      <pubDate>Tue, 06 Jan 2026 05:00:00 GMT</pubDate>
      <description>BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing</description>
    </item>
    <item>
      <title>Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting</title>
      <link>https://6ix.com/company/stoke-therapeutics-inc/news/biogen-and-stoke-therapeutics-present-data-further-support-disease-modifying-0</link>
      <guid isPermaLink="true">https://6ix.com/company/stoke-therapeutics-inc/news/biogen-and-stoke-therapeutics-present-data-further-support-disease-modifying-0</guid>
      <pubDate>Fri, 05 Dec 2025 05:00:00 GMT</pubDate>
      <description>—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs) demonstrate durable</description>
    </item>
    <item>
      <title>Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting</title>
      <link>https://6ix.com/company/stoke-therapeutics-inc/news/stoke-therapeutics-and-biogen-present-data-further-support-disease-modifying</link>
      <guid isPermaLink="true">https://6ix.com/company/stoke-therapeutics-inc/news/stoke-therapeutics-and-biogen-present-data-further-support-disease-modifying</guid>
      <pubDate>Fri, 05 Dec 2025 05:00:00 GMT</pubDate>
      <description>—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs) demonstrate durable</description>
    </item>
    <item>
      <title>Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting</title>
      <link>https://6ix.com/company/stoke-therapeutics-inc/news/stoke-therapeutics-and-biogen-announce-presentations-2025-american-epilepsy-society</link>
      <guid isPermaLink="true">https://6ix.com/company/stoke-therapeutics-inc/news/stoke-therapeutics-and-biogen-announce-presentations-2025-american-epilepsy-society</guid>
      <pubDate>Mon, 01 Dec 2025 05:00:00 GMT</pubDate>
      <description>– New analyses from the ongoing open label extension (OLE) studies and findings from electroencephalogram (EEG) assessments in patients with Dravet syndrome</description>
    </item>
    <item>
      <title>Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments</title>
      <link>https://6ix.com/company/stoke-therapeutics-inc/news/biogen-and-stoke-therapeutics-announce-publication-two-year-natural-history-data-0</link>
      <guid isPermaLink="true">https://6ix.com/company/stoke-therapeutics-inc/news/biogen-and-stoke-therapeutics-announce-publication-two-year-natural-history-data-0</guid>
      <pubDate>Mon, 17 Nov 2025 05:00:00 GMT</pubDate>
      <description>– Despite treatment with standard-of-care anti-seizure medicines, children with Dravet syndrome experienced high seizure burden and plateaued in</description>
    </item>
    <item>
      <title>Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments</title>
      <link>https://6ix.com/company/stoke-therapeutics-inc/news/stoke-therapeutics-and-biogen-announce-publication-two-year-natural-history-data</link>
      <guid isPermaLink="true">https://6ix.com/company/stoke-therapeutics-inc/news/stoke-therapeutics-and-biogen-announce-publication-two-year-natural-history-data</guid>
      <pubDate>Mon, 17 Nov 2025 05:00:00 GMT</pubDate>
      <description>– Despite treatment with standard-of-care anti-seizure medicines, children with Dravet syndrome experienced high seizure burden and plateaued in</description>
    </item>
    <item>
      <title>Stoke Therapeutics to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference</title>
      <link>https://6ix.com/company/stoke-therapeutics-inc/news/stoke-therapeutics-present-guggenheim-2nd-annual-healthcare-innovation-conference</link>
      <guid isPermaLink="true">https://6ix.com/company/stoke-therapeutics-inc/news/stoke-therapeutics-present-guggenheim-2nd-annual-healthcare-innovation-conference</guid>
      <pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
      <description>BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing</description>
    </item>
    <item>
      <title>Stoke Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates</title>
      <link>https://6ix.com/company/stoke-therapeutics-inc/news/stoke-therapeutics-reports-third-quarter-2025-financial-results-and-provides-business</link>
      <guid isPermaLink="true">https://6ix.com/company/stoke-therapeutics-inc/news/stoke-therapeutics-reports-third-quarter-2025-financial-results-and-provides-business</guid>
      <pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
      <description>– Global Phase 3 EMPEROR study patient recruitment ongoing in the U.S., UK, and Japan with more than 20 patients randomized to zorevunersen or sham; Study on</description>
    </item>
    <item>
      <title>Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2025 Business and Financial Updates</title>
      <link>https://6ix.com/company/stoke-therapeutics-inc/news/stoke-therapeutics-host-webcast-and-conference-call-discuss-third-quarter-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/stoke-therapeutics-inc/news/stoke-therapeutics-host-webcast-and-conference-call-discuss-third-quarter-2025</guid>
      <pubDate>Thu, 30 Oct 2025 04:00:00 GMT</pubDate>
      <description>BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing</description>
    </item>
    <item>
      <title>Stoke Therapeutics Presents Two-Year Natural History Data from Patients with Autosomal Dominant Optic Atrophy (ADOA)</title>
      <link>https://6ix.com/company/stoke-therapeutics-inc/news/stoke-therapeutics-presents-two-year-natural-history-data-patients-autosomal-dominant</link>
      <guid isPermaLink="true">https://6ix.com/company/stoke-therapeutics-inc/news/stoke-therapeutics-presents-two-year-natural-history-data-patients-autosomal-dominant</guid>
      <pubDate>Mon, 20 Oct 2025 04:00:00 GMT</pubDate>
      <description>– Data provide insights that informed the Phase 1 study of STK-002 as a potential disease-modifying medicine for ADOA, including disease etiology,</description>
    </item>
  </channel>
</rss>